Cytotoxic T lymphocyte activity in children infected with HIV. 1994

K S Froebel, and M C Aldhous, and J Y Mok, and J Hayley, and M Arnott, and J F Peutherer
Department of Medicine, University of Edinburgh, United Kingdom.

Of the Edinburgh cohort of approximately 130 children born to HIV-infected women, 9 are infected and alive. This article describes results from the first 18 months of a natural history study of seven of these, and two adopted children, studying the CD8 T cell-mediated cytotoxicity against HIV proteins (Gag, Tat, Pol, and Env), over time, and relating it to clinical progression and viral activity. Autologous EBV cell lines infected with vaccinia-HIV constructs were used as target cells, and bulk-cultured peripheral blood mononuclear cells as effector cells. The children ranged in age from 0 to 93 months, with six of the nine showing CTL activity to one or more HIV proteins. The specificity of the response was directed against Tat in the younger children, switching to Pol, then Gag or Env. Preliminary analysis of virological data showed no association between CTL and virus activity. The children with CTLs tended to be well clinically, but the cohort needs to be studied longer before conclusions can be made about CTL activity and HIV disease progression. Cytotoxic T lymphocyte activity has also been observed in two children diagnosed as HIV uninfected. These results show the importance of looking at CTL specificity, and may have implications in vaccine design.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011251 Pregnancy Complications, Infectious The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION. Complications, Infectious Pregnancy,Infectious Pregnancy Complications,Maternal Sepsis,Pregnancy, Infectious Complications,Sepsis during Pregnancy,Sepsis in Pregnancy,Infectious Pregnancy Complication,Pregnancy Complication, Infectious,Sepsis in Pregnancies,Sepsis, Maternal
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic

Related Publications

K S Froebel, and M C Aldhous, and J Y Mok, and J Hayley, and M Arnott, and J F Peutherer
November 1998, AIDS (London, England),
K S Froebel, and M C Aldhous, and J Y Mok, and J Hayley, and M Arnott, and J F Peutherer
January 1999, AIDS research and human retroviruses,
K S Froebel, and M C Aldhous, and J Y Mok, and J Hayley, and M Arnott, and J F Peutherer
November 2000, Annals of the New York Academy of Sciences,
K S Froebel, and M C Aldhous, and J Y Mok, and J Hayley, and M Arnott, and J F Peutherer
November 1997, Journal of virology,
K S Froebel, and M C Aldhous, and J Y Mok, and J Hayley, and M Arnott, and J F Peutherer
April 2006, PLoS biology,
K S Froebel, and M C Aldhous, and J Y Mok, and J Hayley, and M Arnott, and J F Peutherer
April 1997, The Journal of experimental medicine,
K S Froebel, and M C Aldhous, and J Y Mok, and J Hayley, and M Arnott, and J F Peutherer
August 2005, AIDS research and human retroviruses,
K S Froebel, and M C Aldhous, and J Y Mok, and J Hayley, and M Arnott, and J F Peutherer
October 1998, Virology,
K S Froebel, and M C Aldhous, and J Y Mok, and J Hayley, and M Arnott, and J F Peutherer
March 1999, The Journal of infectious diseases,
K S Froebel, and M C Aldhous, and J Y Mok, and J Hayley, and M Arnott, and J F Peutherer
March 2004, AIDS (London, England),
Copied contents to your clipboard!